CXCL12 and pancreatic neoplasm: Anti-CXCL12 (NOX-A12) combined with pembrolizumab can prolong the time on trial treatment compared with their last standard treatment and activate the Th1 immune response in patients with metastatic colorectal and pancreatic cancer [30].